Full Press Release Details
BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.
VSTM Positive Sentiment
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
Key Takeaway: Verastem Oncology has published two-year median follow-up data from the RAMP 201 study in Gynecologic Oncology. The results highlight the durable clinical benefits and manageable safety profile of AVMAPKI® FAKZYNJA® in treating recurrent low-grade serous ovarian cancer. This reinforces the treatment's potential in this patient population.
Market Sentiment Analysis
POSITIVE FACTORS
- Durable clinical benefit observed in long-term results.
- Manageable safety profile reported for the treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+104%
120-day peak, hindsight
Typical move
8.7%
average across 8 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
VS-7375
Phase 2 · Colorectal Cancer
Frequently Asked Questions
What is the RAMP 201 study about?
The RAMP 201 study evaluates the efficacy and safety of AVMAPKI® FAKZYNJA® in recurrent low-grade serous ovarian cancer.
What were the findings of the RAMP 201 study?
The study reported durable clinical benefits and a manageable safety profile over a two-year follow-up.
Where were the results published?
The results were published in the journal Gynecologic Oncology.
What is AVMAPKI® FAKZYNJA®?
AVMAPKI® FAKZYNJA® consists of avutometinib capsules and defactinib tablets used in cancer treatment.